Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.
University of Texas Southwestern Medical Center, Dallas, TX, USA. royfleischmann@radiantresearch.com
Roy
R
Fleischmann
Dave
D
Shealy
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000276:immunology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D051379:Mice; D015202:Protein Engineering; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha